These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23569059)

  • 1. Australia's 'fourth hurdle' drug review comparing costs and benefits holds lessons for the United States.
    Lopert R; Elshaug AG
    Health Aff (Millwood); 2013 Apr; 32(4):778-87. PubMed ID: 23569059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based decision-making within Australia's pharmaceutical benefits scheme.
    Lopert R
    Issue Brief (Commonw Fund); 2009 Jul; 60():1-13. PubMed ID: 19639714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are cancer drugs less likely to be recommended for listing by the Pharmaceutical Benefits Advisory Committee in Australia?
    Chim L; Kelly PJ; Salkeld G; Stockler MR
    Pharmacoeconomics; 2010; 28(6):463-75. PubMed ID: 20465315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
    Doran E; Alexander Henry D
    J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A perspective on Australia's National Medicines Policy.
    Tett SE
    Can J Clin Pharmacol; 2004; 11(1):e28-38. PubMed ID: 15226524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges to pharmaceutical policymaking: lessons from Australia's national medicines policy.
    Lipworth W; Doran E; Kerridge I; Day R
    Aust Health Rev; 2014 May; 38(2):160-8. PubMed ID: 24589424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compared to US practice, evidence-based reviews in Europe appear to lead to lower prices for some drugs.
    Cohen J; Malins A; Shahpurwala Z
    Health Aff (Millwood); 2013 Apr; 32(4):762-70. PubMed ID: 23569057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Balancing health and industrial policy objectives in the pharmaceutical sector: lessons from Australia.
    Morgan S; McMahon M; Greyson D
    Health Policy; 2008 Aug; 87(2):133-45. PubMed ID: 18295927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciding which drugs get onto the formulary: a value-based approach.
    Seigfried RJ; Corbo T; Saltzberg MT; Reitz J; Bennett DA
    Value Health; 2013; 16(5):901-6. PubMed ID: 23947985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Australia's National Medicines Policy using geographical mapping.
    Roughead EE; Monteith GR; Harvey KJ; Tett SE
    Intern Med J; 2002 Mar; 32(3):66-71. PubMed ID: 11885845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug policy down under: Australia's pharmaceutical benefits scheme.
    Duckett SJ
    Health Care Financ Rev; 2004; 25(3):55-67. PubMed ID: 15229996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmaceuticals in Australia: priorities in a teaching hospital.
    Kearney BJ
    Physician Exec; 1993; 19(5):63-7. PubMed ID: 10130953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Australia's healthcare system.
    Cooper DA
    J Int Assoc Physicians AIDS Care; 1996 Mar; 2(3):14-6. PubMed ID: 11363342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
    Robertson J; Walkom EJ; Henry DA
    Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription drug accessibility and affordability in the United States and abroad.
    Morgan S; Kennedy J
    Issue Brief (Commonw Fund); 2010 Jun; 89():1-12. PubMed ID: 20614652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmaceuticals: Medicare Modernization Act--2005. End of Year Issue Brief.
    Seay M
    Issue Brief Health Policy Track Serv; 2005 Dec; ():1-21. PubMed ID: 16710928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.